Predicate |
Object |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-65 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6803 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6855 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6851 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6863 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6849 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6865 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6857 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D207-335 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4025 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-454 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-65 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-07 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-05 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4025 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 |
filingDate |
2021-11-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate |
2022-02-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
JP-2022025122-A |
titleOfInvention |
Antibody drug conjugates (ADCs) and antibody prodrug conjugates (APDCs) with enzyme-cleaving groups |
abstract |
PROBLEM TO BE SOLVED: To provide a peptide derivative which can be released by the action of a tumor-related enzyme on a binder complex in order to further enhance tumor selectivity of ADCs and their metabolites. A novel antibody prodrug conjugate (APDC) to which an antibody binds to an inactive precursor compound of a kinesin spindle protein inhibitor, and an antibody drug conjugate (ADC) and a method for producing the APDC or ADC. offer. [Selection diagram] Fig. 3 |
priorityDate |
2015-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |